Modernize 1

Participant app for the Modernize 1 study

This app is intended for use by participants in the Modernize 1 study and requires an invitation and activation code from the study site to register. A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1). This study has been reviewed and approved by the appropriate regulatory body, e.g. Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

Key App Features:

• Patient Onboarding – complete study app registration and education
• Activities – complete scheduled or on-demand study tasks and assessments
• Dashboard – review overall progress in the study and current activities
• Resources – view study information in the Learn section of the app
• Profile – manage account details and app settings
• Notifications – receive in-app reminders
• Telehealth – conduct scheduled virtual visits with your study site

About THREAD: THREAD’s® purpose is to leverage its clinical research platform to enable studies for everyone, everywhere. The company’s uniquely combined clinical research technology and consulting services help life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and centered on the patient.